AstraZeneca's IMFINZI Combination Therapy Shows Survival Benefits in Bladder Cancer Trial
Event summary
- AstraZeneca's VOLGA Phase III trial showed perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin (EV) significantly improved event-free survival (EFS) and overall survival (OS) in muscle-invasive bladder cancer (MIBC) patients ineligible for cisplatin-based chemotherapy.
- The trial randomized 695 patients across 182 centers in 25 countries, with dual primary endpoints of EFS and OS.
- IMFINZI plus IMJUDO demonstrated a favorable trend for OS, though not statistically significant at this interim analysis.
- The safety profile of the combination therapies was consistent with known safety profiles, with no new safety signals identified.
The big picture
AstraZeneca's positive VOLGA trial results reinforce the strategic importance of IMFINZI in the bladder cancer treatment landscape. With up to 50% of MIBC patients ineligible for cisplatin, the need for effective alternatives is critical. This success builds on AstraZeneca's previous positive readouts in bladder cancer, solidifying IMFINZI's role as a key immunotherapy in the curative-intent setting. The company's focus on perioperative treatments aligns with broader industry trends toward earlier intervention in oncology.
What we're watching
- Regulatory Pathway
- Whether AstraZeneca can secure global regulatory approvals for IMFINZI in combination with EV based on these interim results.
- Competitive Dynamics
- How this positive readout positions IMFINZI as the immunotherapy backbone in early-stage bladder cancer, potentially expanding its market share.
- Clinical Validation
- The pace at which additional data from the VOLGA trial will be presented at medical meetings and shared with regulatory authorities.
Related topics